KR100757155B1 - 저용량의 엔테카비르 제제 및 그의 용도 - Google Patents
저용량의 엔테카비르 제제 및 그의 용도 Download PDFInfo
- Publication number
- KR100757155B1 KR100757155B1 KR1020027011143A KR20027011143A KR100757155B1 KR 100757155 B1 KR100757155 B1 KR 100757155B1 KR 1020027011143 A KR1020027011143 A KR 1020027011143A KR 20027011143 A KR20027011143 A KR 20027011143A KR 100757155 B1 KR100757155 B1 KR 100757155B1
- Authority
- KR
- South Korea
- Prior art keywords
- entecavir
- composition
- carrier substrate
- mixtures
- delete
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
성분 | 양 중량/중량% | 정제 1개 당의 양 |
엔테카비르 | 0.5 | 0.50 mg |
락토스 1수화물, NF | 60.00 | 60.00 mg |
미세결정질 셀룰로오스, NF | 32.50 | 32.50 mg |
크로스포비돈, NF | 4.00 | 4.00 mg |
포비돈, USP | 2.50 | 2.50 mg |
마그네슘 스테아레이트, NF | 0.50 | 0.50 mg |
정제된 물, USP* | 충분량 | -- |
총 | 100.00 | 100.00 mg |
*건조 제거함 |
성분 | 양 중량/중량% | 정제 1개 당의 양 |
엔테카비르 | 0.1 | 0.1 mg |
락토스 1수화물, NF | 60.00 | 60.00 mg |
미세결정질 셀룰로오스, NF | 35.39 | 35.39 mg |
크로스포비돈, NF | 4.00 | 4.00 mg |
포비돈, USP | 0.01 | 0.01 mg |
마그네슘 스테아레이트, NF | 0.5 | 0.5 mg |
정제된 물, USP* | 충분량 | -- |
총 | 100.00 | 100.00 mg |
*건조 제거함 |
성분 | 양 중량/중량% | 정제 1개 당의 양 |
엔테카비르 | 0.01 | 0.01 mg |
미세결정질 셀룰로오스, NF | 93.24 | 93.24 mg |
크로스포비돈, NF | 4.00 | 4.00 mg |
포비돈, USP | 2.50 | 2.50 mg |
마그네슘 스테아레이트, NF | 0.25 | 0.25 mg |
정제된 물, USP* | 충분량 | --- |
총 | 100.00 | 100.00 mg |
*건조 제거함 |
성분 | 양 중량/중량% | 캡슐 1개 당의 양 |
엔테카비르 | 10.00 | 10.00 mg |
미세결정질 셀룰로오스, NF | 82.03 | 82.03 mg |
크로스포비돈, NF | 4.00 | 4.00 mg |
포비돈, USP | 2.50 | 2.50 mg |
마그네슘 스테아레이트, NF | 0.25 | 0.25 mg |
염산 | 1.22 | 1.22 mg |
정제된 물, USP* | 충분량 | -- |
총 | 100.00 | 100.00 mg |
캡슐 셀 ---- *건조 제거함 |
성분 | 양 중량/중량% | 캡슐 1개 당의 양 |
엔테카비르 | 0.05 | 0.05 mg |
인산이칼슘, NF | 93.20 | 93.20 mg |
크로스포비돈, NF | 4.00 | 4.00 mg |
히드록시프로필 셀룰로오스, NF | 2.50 | 2.50 mg |
마그네슘 스테아레이트, NF | 0.25 | 0.25 mg |
정제된 물, USP* | 충분량 | --- |
총 | 100.00 | 100.00 mg |
캡슐 셀 ---- *건조 제거함 |
성분 | 양 중량/중량% | 정제 1개 당의 양 |
엔테카비르 | 1.00 | 1.00 mg |
만니톨, NF | 90.00 | 90.00 mg |
크로스카르멜로스 소듐, NF | 4.00 | 4.00 mg |
메킬 셀룰로오스, NF | 2.50 | 2.50 mg |
스테아르산, NF | 2.50 | 2.50 mg |
정제된 물, USP* | 충분량 | --- |
총 | 100.00 | 100.00 mg |
*건조 제거함 |
성분 | 양 중량/중량% | 정제1 1개 당의 양 |
오파드리(Opadry(등록상표)) | 1 내지 10 | 1 내지 10 mg |
가소제2 | 0 내지 10 | 0 내지 10 mg |
정제된 물, USP* | 충분량 | --- |
*건조 제거함 오파드리(등록상표)는 시판 입수가능하고, 히드록시프로필메틸셀룰로오스, 이산화티탄, 폴리에틸렌 글리콜, 폴리소르베이트 80, 합성 황색 산화철 및 합성 적색 산화철을 포함한다. 1 정제 중량을 100 mg으로 가정하여 계산하였다. 2 적절한 가소제는 디에틸 시트레이트 및 트리에틸 시트레이트이다. |
Claims (23)
- 담체 기질의 표면에 부착된 0.5 내지 1.0 mg의 엔테카비르(entecavir)를 포함하는, B형 간염 바이러스 감염을 치료하기 위한 1일 1회 투여에 효과적인 제약 조성물.
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 제1항에 있어서, 상기 엔테카비르가 0.5 mg으로 존재하는 조성물.
- 제1항에 있어서, 상기 엔테카비르가 1.0 mg의 양으로 존재하는 조성물.
- 제1항에 있어서, 정제 또는 캡슐제 형태인 조성물.
- 제1항에 있어서, 1종 이상의 다른 제약상 활성 물질을 함유하는 조성물.
- 삭제
- 제1항에 있어서, 상기 담체 기질이 락토스, 미세결정질 셀룰로오스, 인산칼슘, 덱스트린, 덱스트로스, 덱스트레이트, 만니톨, 소르비톨 및 수크로스, 및 이들의 혼합물로부터 선택되고, 상기 엔테카비르가 포비돈, 메틸셀룰로오스, 히드록시메틸셀룰로오스, 히드록시프로필메틸셀룰로오스, 히드록시프로필셀룰로오스, 히드록시에틸셀룰로오스, 젤라틴, 구아 검 및 크산탄 검, 및 이들의 혼합물로부터 선택되는 중합체 재료인 제약상 허용가능한 점착성 물질에 의해 상기 기질에 부착되는 것인, 담체 기질의 표면에 부착되는 0.5 내지 1.0 mg의 엔테카비르를 포함하는 조성물.
- 삭제
- 제12항에 있어서, 마그네슘 스테아레이트, 스테아르산, 소듐 스테아릴 푸마레이트 및 소듐 라우릴 술페이트, 및 이들의 혼합물로부터 선택되는 윤활제와, 크로스포비돈, 크로스카르멜로스 소듐, 글리콜산나트륨 전분, 예비젤라틴화된 전분 및 옥수수 전분, 및 이들의 혼합물로부터 선택되는 붕해제를 포함하는 조성물.
- 제1항에 있어서, 담체 기질의 표면에 엔테카비르를 부착시키는 점착성 물질에 의해 코팅된 엔테카비르, 윤활제 및 붕해제를 포함하며,상기 엔테카비르는 조성물의 0.5 내지 1 중량%로 존재하고, 상기 점착성 물질은 조성물의 0.01 내지 10 중량%로 존재하고, 상기 담체 기질은 조성물의 80 내지 95 중량%로 존재하고, 상기 붕해제는 조성물의 1 내지 7 중량%로 존재하고, 상기 윤활제는 조성물의 0.1 내지 5 중량%로 존재하는 것인 조성물.
- 제15항에 있어서,상기 점착성 물질이 포비돈, 메틸셀룰로오스, 히드록시메틸셀룰로오스, 히드록시프로필메틸셀룰로오스, 히드록시프로필셀룰로오스, 히드록시에틸셀룰로오스, 젤라틴, 구아 검, 크산탄 검, 및 이들의 혼합물로부터 선택되고,상기 담체 기질이 미세결정질 셀룰로오스, 인산칼슘, 덱스트린, 덱스트로스, 덱스트레이트, 만니톨, 소르비톨, 수크로스, 및 이들의 혼합물로부터 선택되고,상기 붕해제가 크로스포비돈, 크로스카르멜로스 소듐, 글리콜산나트륨 전분, 예비젤라틴화된 전분 및 옥수수 전분, 및 이들의 혼합물로부터 선택되고,상기 윤활제가 마그네슘 스테아레이트, 스테아르산, 소듐 스테아릴 푸마레이트, 소듐 라우릴 술페이트, 및 이들의 혼합물로부터 선택되는 것인 조성물.
- 제16항에 있어서, 상기 점착성 물질이 포비돈이고; 상기 담체 기질이 미세결정질 셀룰로오스이고; 상기 붕해제가 크로스포비돈이고; 상기 윤활제가 마그네슘 스테아레이트인 조성물.
- 삭제
- 제16항에 있어서, 외부 필름 코팅을 가지는 조성물.
- 삭제
- (a) 물, 또는 산성 또는 염기성 pH를 가지는 물인 용매 중에 엔테카비르 및 점착성 물질을 용해시키는 단계,(b) 상기 단계 (a)의 용액을 운동 중인 담체 기질 상에 분무하여 상기 엔테카비르를 담체 기질의 표면에 부착시키는 단계,(c) 상기 단계 (b)의 코팅된 담체 기질을 건조시켜 상기 용매를 제거하는 단계, 및(d) 상기 단계 (c)의 건조 및 코팅된 담체 기질을 다른 바람직한 성분과 혼합하여 제약 조성물을 형성하는 단계를 포함하는, 0.5 내지 1.0 mg의 엔테카비르를 포함하는 경구 투여용 제약 조성물의 제조 방법.
- 삭제
- 제21항에 있어서,상기 담체 기질을 분무 단계 (b) 동안 기계적 교반에 의해 운동을 유지시키고, 단계 (c)에서 상기 코팅된 담체 기질을 트레이 건조기 또는 유동층 건조기 내에서 건조시키거나; 또는상기 담체 기질을 분무 단계 (b) 동안 기류에 의해 운동을 유지시키고, 단계 (c)에서 상기 코팅된 담체 기질을 기류 교반에 의해 또한 건조시키는 방법.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18567200P | 2000-02-29 | 2000-02-29 | |
US60/185,672 | 2000-02-29 | ||
US22131300P | 2000-07-28 | 2000-07-28 | |
US60/221,313 | 2000-07-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20020082230A KR20020082230A (ko) | 2002-10-30 |
KR100757155B1 true KR100757155B1 (ko) | 2007-09-07 |
Family
ID=26881354
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020027011143A KR100757155B1 (ko) | 2000-02-29 | 2001-01-26 | 저용량의 엔테카비르 제제 및 그의 용도 |
Country Status (35)
Country | Link |
---|---|
US (1) | US6627224B2 (ko) |
EP (2) | EP1267880B2 (ko) |
JP (3) | JP5140222B2 (ko) |
KR (1) | KR100757155B1 (ko) |
AR (1) | AR027965A1 (ko) |
AT (1) | ATE312613T1 (ko) |
AU (1) | AU2001229775A1 (ko) |
BG (1) | BG65815B1 (ko) |
BR (1) | BRPI0108435B8 (ko) |
CA (1) | CA2401569C (ko) |
CO (1) | CO5261593A1 (ko) |
CZ (1) | CZ303395B6 (ko) |
DE (1) | DE60115870T3 (ko) |
DK (1) | DK1267880T4 (ko) |
EA (1) | EA006181B1 (ko) |
EE (1) | EE05442B1 (ko) |
EG (1) | EG24408A (ko) |
ES (1) | ES2253403T5 (ko) |
GE (1) | GEP20053504B (ko) |
HK (1) | HK1048771A1 (ko) |
HR (1) | HRP20020649A2 (ko) |
HU (1) | HU230698B1 (ko) |
IL (1) | IL150447A0 (ko) |
MX (1) | MXPA02008359A (ko) |
MY (1) | MY127422A (ko) |
NO (1) | NO324014B1 (ko) |
NZ (1) | NZ520024A (ko) |
PE (1) | PE20020770A1 (ko) |
PL (1) | PL201411B1 (ko) |
RS (1) | RS51561B (ko) |
SI (1) | SI1267880T2 (ko) |
SK (1) | SK288008B6 (ko) |
TW (1) | TWI287988B (ko) |
UA (1) | UA84534C2 (ko) |
WO (1) | WO2001064221A1 (ko) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20120138908A (ko) * | 2011-06-16 | 2012-12-27 | 건일제약 주식회사 | 엔테카비르를 함유하는 미립구 및 이의 제조방법 |
KR101512895B1 (ko) | 2013-08-09 | 2015-04-16 | 대화제약 주식회사 | 엔테카비어를 포함하는 약학적 조성물의 제조방법 |
KR20230112817A (ko) | 2022-01-21 | 2023-07-28 | 한림대학교 산학협력단 | 피루브산 및 pdk 억제제를 포함하는 뇌질환의 예방 또는 치료용 조성물 |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1267880T2 (sl) * | 2000-02-29 | 2010-04-30 | Bristol Myers Squibb Co | Formulacija z nizko dozo entekavirja in uporaba |
MY131488A (en) * | 2002-04-08 | 2007-08-30 | Bristol Myers Squibb Co | Low dose liquid entecavir formulations and use |
AR040588A1 (es) | 2002-07-26 | 2005-04-13 | Schering Corp | Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa |
EP2433941A1 (en) * | 2002-12-11 | 2012-03-28 | Bristol-Myers Squibb Company | Process for isolating the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one |
AU2004206821C1 (en) | 2003-01-14 | 2009-10-01 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
ES2596827T3 (es) | 2003-11-17 | 2017-01-12 | Biomarin Pharmaceutical Inc. | Tratamiento de la fenilcetonuria con BH4 |
KR20060125805A (ko) * | 2003-11-18 | 2006-12-06 | 베링거 인겔하임 인터내셔날 게엠베하 | 고체 약제학적 제제 형태 |
US7511139B2 (en) * | 2004-06-04 | 2009-03-31 | Bristol-Myers Squibb Company | Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation |
JP4756153B2 (ja) * | 2004-08-27 | 2011-08-24 | 富士製薬工業株式会社 | 低成分含量の錠剤の製造方法 |
US20060127451A1 (en) * | 2004-09-23 | 2006-06-15 | Michael Augello | Coating composition |
TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
CN101245068A (zh) * | 2007-02-14 | 2008-08-20 | 浙江医药股份有限公司新昌制药厂 | 结晶型态的恩替卡韦及其制备方法和其药物组合物及用途 |
AR065809A1 (es) | 2007-03-22 | 2009-07-01 | Bristol Myers Squibb Co | Formulaciones farmaceuticas que contienen un inhibidor sglt2 |
AU2010315414B2 (en) * | 2009-10-28 | 2015-07-09 | Mcneil-Ppc, Inc. | Fast dissolving/disintegrating coating compositions |
DE102009060194A1 (de) | 2009-12-23 | 2011-06-30 | ratiopharm GmbH, 89079 | Orale Darreichungsform umfassend Entecavir |
EA201290556A1 (ru) * | 2009-12-23 | 2013-01-30 | Рациофарм Гмбх | Оральная лекарственная форма, включающая энтекавир |
EP2536411A4 (en) * | 2010-02-18 | 2013-08-07 | Univ Princeton | HEMMER OF THE METABOLISM OF LOW-CHAIN AND VERY LOW-FATTYED FATTY ACIDS AS AN ANTIVIRUS ACTIVE SUBSTANCES WITH A WIDE SPECTRUM |
NZ602622A (en) | 2010-03-31 | 2015-01-30 | Millennium Pharm Inc | Derivatives of 1-amino-2-cyclopropylethylboronic acid |
WO2012048455A1 (zh) * | 2010-10-12 | 2012-04-19 | 武汉大学 | 一种抗病毒透皮吸收贴片及其制备方法 |
EP2508172A1 (en) | 2011-04-06 | 2012-10-10 | Zentiva, a.s. | Stable and uniform formulations of entecavir and preparation method thereof |
KR101439635B1 (ko) | 2011-11-01 | 2014-09-11 | 대원제약주식회사 | 안정성이 향상된 엔테카비어를 함유하는 약학적 조성물 및 그 제조방법 |
IN2011CH03893A (ko) * | 2011-11-14 | 2015-08-21 | Hetero Research Foundation | |
EP2644197A1 (en) * | 2012-03-26 | 2013-10-02 | Sanovel Ilac Sanayi ve Ticaret A.S. | Novel Pharmaceutical Compositions of Entecavir |
EP2644196B1 (en) * | 2012-03-26 | 2019-09-18 | Arven Ilac Sanayi ve Ticaret A.S. | Pharmaceutical compositions of Entecavir |
KR101285008B1 (ko) * | 2012-04-18 | 2013-07-10 | 제일약품주식회사 | 저용량 엔테카비어의 경구투여 제제의 제조방법 |
CA2779052A1 (en) * | 2012-05-31 | 2013-11-30 | Pharmascience Inc. | Pharmaceutical composition of entecavir and process of manufacturing |
CN103908436B (zh) * | 2012-12-29 | 2016-02-10 | 安徽贝克生物制药有限公司 | 一种速释型恩替卡韦组合物 |
WO2015194923A1 (ko) * | 2014-06-20 | 2015-12-23 | 주식회사 씨티씨바이오 | 엔테카비르를 유효성분으로 포함하는 약학 제제 및 이의 제조방법 |
US11273129B2 (en) | 2015-09-30 | 2022-03-15 | Daicel Corporation | Particle composition for easy-to-use solid preparation and easy-to-use solid preparation including said particle composition |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0481754A2 (en) | 1990-10-18 | 1992-04-22 | E.R. Squibb & Sons, Inc. | Hydroxymethyl(methylenecyclopentyl)Purines and Pyrimidines |
WO2000009531A2 (en) * | 1998-08-10 | 2000-02-24 | Novirio Pharmaceuticals Limited | β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3836618A (en) * | 1971-12-23 | 1974-09-17 | American Home Prod | Process for the uniform distribution of a drug on a granulated base |
US4513008A (en) * | 1982-07-30 | 1985-04-23 | The Vinoxen Company, Inc. | Virucidal compositions and therapy |
US4489026A (en) * | 1982-09-07 | 1984-12-18 | The Upjohn Company | Process for preparing solid unit dosage forms of ultra-low dose drugs |
US4631284A (en) * | 1984-11-19 | 1986-12-23 | Mallinckrodt, Inc. | Acetaminophen compositions containing low doses of chlorpheniramine maleate, method for preparing same and tablets formed therefrom |
JPH08208478A (ja) * | 1994-10-14 | 1996-08-13 | Japan Energy Corp | 抗エイズ薬製剤およびその製造方法 |
DE19714024A1 (de) * | 1996-04-04 | 1997-11-20 | L A B Ges Fuer Pharmakologisch | Verfahren zur Herstellung von gering dosierten freifließenden und/oder direktkomprimierbaren Pulversystemen |
AU4090697A (en) | 1996-09-03 | 1998-03-26 | Bristol-Myers Squibb Company | Improved process for preparing the antiviral agent {1s-(1alpha, 3alpha, 4beta)}-2-amino-1,9-dihydro-9-{4-hydroxy-3-(hydroxymethyl)-2 -methylenecyclopentyl}-6h-purin-6-one |
US5997905A (en) * | 1998-09-04 | 1999-12-07 | Mcneil-Ppc | Preparation of pharmaceutically active particles |
GB9820420D0 (en) | 1998-09-18 | 1998-11-11 | Glaxo Group Ltd | Antiviral combinations |
GB9820417D0 (en) | 1998-09-18 | 1998-11-11 | Glaxo Group Ltd | Antiviral combinations |
GB9820416D0 (en) | 1998-09-18 | 1998-11-11 | Glaxo Group Ltd | Antiviral combinations |
US6432966B2 (en) † | 1999-10-29 | 2002-08-13 | Smithkline Beecham Corporation | Antiviral combinations |
SI1267880T2 (sl) * | 2000-02-29 | 2010-04-30 | Bristol Myers Squibb Co | Formulacija z nizko dozo entekavirja in uporaba |
-
2001
- 2001-01-26 SI SI200130502T patent/SI1267880T2/sl unknown
- 2001-01-26 RS YU63002A patent/RS51561B/sr unknown
- 2001-01-26 IL IL15044701A patent/IL150447A0/xx active IP Right Grant
- 2001-01-26 EA EA200200812A patent/EA006181B1/ru not_active IP Right Cessation
- 2001-01-26 WO PCT/US2001/002630 patent/WO2001064221A1/en active IP Right Grant
- 2001-01-26 NZ NZ520024A patent/NZ520024A/en not_active IP Right Cessation
- 2001-01-26 MX MXPA02008359A patent/MXPA02008359A/es active IP Right Grant
- 2001-01-26 BR BRPI0108435 patent/BRPI0108435B8/pt not_active IP Right Cessation
- 2001-01-26 DE DE60115870T patent/DE60115870T3/de not_active Expired - Lifetime
- 2001-01-26 EP EP01955090A patent/EP1267880B2/en not_active Expired - Lifetime
- 2001-01-26 HU HU0500558A patent/HU230698B1/hu unknown
- 2001-01-26 UA UA2002097732A patent/UA84534C2/uk unknown
- 2001-01-26 PL PL366102A patent/PL201411B1/pl unknown
- 2001-01-26 ES ES01955090T patent/ES2253403T5/es not_active Expired - Lifetime
- 2001-01-26 GE GE4868A patent/GEP20053504B/en unknown
- 2001-01-26 EE EEP200200484A patent/EE05442B1/xx unknown
- 2001-01-26 EP EP05020938A patent/EP1642582A1/en not_active Withdrawn
- 2001-01-26 CZ CZ20022902A patent/CZ303395B6/cs not_active IP Right Cessation
- 2001-01-26 DK DK01955090.4T patent/DK1267880T4/da active
- 2001-01-26 JP JP2001563118A patent/JP5140222B2/ja not_active Expired - Lifetime
- 2001-01-26 AT AT01955090T patent/ATE312613T1/de active
- 2001-01-26 AU AU2001229775A patent/AU2001229775A1/en not_active Abandoned
- 2001-01-26 SK SK1165-2002A patent/SK288008B6/sk not_active IP Right Cessation
- 2001-01-26 CA CA002401569A patent/CA2401569C/en not_active Expired - Lifetime
- 2001-01-26 KR KR1020027011143A patent/KR100757155B1/ko active IP Right Review Request
- 2001-02-07 MY MYPI20010532A patent/MY127422A/en unknown
- 2001-02-22 TW TW090104020A patent/TWI287988B/zh not_active IP Right Cessation
- 2001-02-23 US US09/792,576 patent/US6627224B2/en not_active Expired - Lifetime
- 2001-02-26 EG EG20010191A patent/EG24408A/xx active
- 2001-02-28 AR ARP010100961A patent/AR027965A1/es not_active Application Discontinuation
- 2001-02-28 CO CO01015910A patent/CO5261593A1/es not_active Application Discontinuation
- 2001-06-12 PE PE2001000552A patent/PE20020770A1/es not_active Application Discontinuation
-
2002
- 2002-07-05 BG BG106905A patent/BG65815B1/bg unknown
- 2002-08-01 HR HRP20020649 patent/HRP20020649A2/hr not_active Application Discontinuation
- 2002-08-28 NO NO20024099A patent/NO324014B1/no not_active IP Right Cessation
-
2003
- 2003-02-14 HK HK03101080.6A patent/HK1048771A1/zh unknown
-
2012
- 2012-08-22 JP JP2012183484A patent/JP2012255017A/ja not_active Revoked
-
2015
- 2015-05-27 JP JP2015107778A patent/JP5921746B2/ja not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0481754A2 (en) | 1990-10-18 | 1992-04-22 | E.R. Squibb & Sons, Inc. | Hydroxymethyl(methylenecyclopentyl)Purines and Pyrimidines |
WO2000009531A2 (en) * | 1998-08-10 | 2000-02-24 | Novirio Pharmaceuticals Limited | β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20120138908A (ko) * | 2011-06-16 | 2012-12-27 | 건일제약 주식회사 | 엔테카비르를 함유하는 미립구 및 이의 제조방법 |
KR101594820B1 (ko) * | 2011-06-16 | 2016-02-17 | 건일제약 주식회사 | 엔테카비르를 함유하는 미립구 및 이의 제조방법 |
KR101512895B1 (ko) | 2013-08-09 | 2015-04-16 | 대화제약 주식회사 | 엔테카비어를 포함하는 약학적 조성물의 제조방법 |
KR20230112817A (ko) | 2022-01-21 | 2023-07-28 | 한림대학교 산학협력단 | 피루브산 및 pdk 억제제를 포함하는 뇌질환의 예방 또는 치료용 조성물 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100757155B1 (ko) | 저용량의 엔테카비르 제제 및 그의 용도 | |
EP2854773B1 (en) | Pharmaceutical composition of entecavir and process of manufacturing | |
ZA200205900B (en) | Low dose entecavir formulation and use. | |
AU2006235960B2 (en) | Low dose entecavir formulation and use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
G170 | Re-publication after modification of scope of protection [patent] | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J301 | Trial decision |
Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20120913 Effective date: 20130430 |
|
J206 | Request for trial to confirm the scope of a patent right | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J301 | Trial decision |
Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20130628 Effective date: 20130905 Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20130404 Effective date: 20130905 |
|
J206 | Request for trial to confirm the scope of a patent right | ||
J121 | Written withdrawal of request for trial | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J302 | Written judgement (patent court) |
Free format text: JUDGMENT (PATENT COURT) FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20131108 Effective date: 20140411 Free format text: JUDGMENT (PATENT COURT) FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20130705 Effective date: 20140411 |
|
J301 | Trial decision |
Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20130729 Effective date: 20140528 Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20131106 Effective date: 20140528 Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20131206 Effective date: 20140528 Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20131122 Effective date: 20140528 |
|
J301 | Trial decision |
Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20130401 Effective date: 20140528 Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20130510 Effective date: 20140528 |
|
J206 | Request for trial to confirm the scope of a patent right | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J204 | Request for invalidation trial [patent] | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J204 | Request for invalidation trial [patent] | ||
J204 | Request for invalidation trial [patent] | ||
J301 | Trial decision |
Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20140821 Effective date: 20150217 Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20140915 Effective date: 20150217 |
|
J206 | Request for trial to confirm the scope of a patent right | ||
J204 | Request for invalidation trial [patent] | ||
J301 | Trial decision |
Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20140729 Effective date: 20150303 Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20140722 Effective date: 20150303 |
|
J204 | Request for invalidation trial [patent] | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J204 | Request for invalidation trial [patent] | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J121 | Written withdrawal of request for trial | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J301 | Trial decision |
Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20141020 Effective date: 20150330 |
|
J301 | Trial decision |
Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20141107 Effective date: 20150413 Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20141010 Effective date: 20150413 |
|
J121 | Written withdrawal of request for trial | ||
J303 | Written judgement (supreme court) |
Free format text: JUDGMENT (SUPREME COURT) FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20140515 Effective date: 20150521 |
|
J122 | Written withdrawal of action (patent court) | ||
J301 | Trial decision |
Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20141114 Effective date: 20150602 |
|
J122 | Written withdrawal of action (patent court) | ||
J301 | Trial decision |
Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20141226 Effective date: 20150630 |
|
FPAY | Annual fee payment |
Payment date: 20150819 Year of fee payment: 9 |
|
J301 | Trial decision |
Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20150314 Effective date: 20151007 Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20150312 Effective date: 20151007 Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20150313 Effective date: 20151008 Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20150313 Effective date: 20151007 Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20150311 Effective date: 20151007 Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20150318 Effective date: 20151008 |
|
J121 | Written withdrawal of request for trial | ||
J301 | Trial decision |
Free format text: TRIAL DECISION FOR INVALIDATION REQUESTED 20150130 Effective date: 20151104 Free format text: TRIAL DECISION FOR INVALIDATION REQUESTED 20150306 Effective date: 20151104 Free format text: TRIAL DECISION FOR INVALIDATION REQUESTED 20141027 Effective date: 20151104 |